Evaluation of High-Pressure Retrograde Coronary Venous Delivery of FGF-2 Protein

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 3, 2004, Pages 422-428

  Fearon, William F ^a,b   Ikeno, Fumiaki ^a   Bailey, Lynn R ^a   Hiatt, Bonnie L ^a   Herity, Niall A ^a   Carter, Andrew J ^a   Fitzgerald, Peter J ^a   Rezaee, Mehrdad ^a   Yeung, Alan C ^a   Yock, Paul G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Coronary disease; Ischemia; Veins

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; LUTETIUM;

ANGIOGENESIS; ANIMAL MODEL; BALLOON CATHETER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; HYPOTENSION; IMPLANTATION; ISOTOPE LABELING; NONHUMAN; REVIEW; STENT; SWAN GANZ CATHETER; SWINE; TREATMENT OUTCOME;

ANIMALS; CORONARY CIRCULATION; CORONARY VESSELS; FIBROBLAST GROWTH FACTOR 2; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; LUTETIUM; MYOCARDIAL ISCHEMIA; MYOCARDIUM; STENTS; SWINE;

EID: 10744229735     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10790     Document Type: Review

References (18)

1. Kornowski R, Fuchs S, Leon M, Epstein S. Delivery strategies to achieve therapeutic myocardial angiogensis. Circulation 2000;101:454-458.
2. Herity NA, Lo ST, Oei F, et al. Selective regional myocardial infiltration by the percutaneous coronary venous route: a novel technique for local drug delivery. Catheter Cardiovasc Interv 2000;51:358-363.
3. Reinhardt CP, Dalhberg S, Tries MA, Marcel R, Leppo JA. Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol 2001;280:H108-H116.
4. Devlin GP, Fort S, Yu E, et al. Effect of a single bolus of intracoronary basic fibroblast growth factor on perfusion in an ischemic porcine model. Can J Cardiol 1999;15:676-682.
5. 165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001;37:616-623.
6. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-630.
7. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587-592.
8. Armstrong WF, Pellikka PA, Ryan T, Crouse L, Zoghbi WA. Stress echocardiography: recommendations for performance and interpretation of stress echocardiography - Stress Echocardiography Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 1998;11:97-104.
9. Fitzgerald PJ, Yock C, Yock PG. Orientation of intracoronary ultrasonography: looking beyond the artery. J Am Soc Echocardiogr 1998;11:13-19.
10. Boekstegers P, von Degenfeld G, Giehrl W, Steinbeck G. Selective suction and pressure-regulated retroinfusion: an effective and safe approach to retrograde protection against myocardial ischemia in patients undergoing normal and high risk percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1998;31:1525-1533.
11. Meisel E, Pfeiffer D, Engelmann L, Tebbenjohanns J, Schubert B, Hahn S, Fleck E, Butter C. Investigation of coronary venous anatomy by retrograde venography in patients with malignant ventricular tachycardia. Circulation 2001;104:442-447.
12. Herity NA, Hiatt BL, Fearon WF, et al. Acute and long-term safety of pressurized myocardial transvenous delivery: confirmation by biochemical, echocardiographic, and histologic parameters. J Am Coll Cardiol 2002;39:10A.
13. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000;7:232-240.
14. Hou D, McLaughlin F, Thiesse M, et al. Widespread myocardial transfection by plasmid encoding del-1 following retrograde coronary venous delivery. Circulation 2001;104:II116.
15. Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997;36:78-85.
16. Lazarous DF, Scheinowitz M, Shou M, et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995;91:145-153.
17. Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharm Exp Ther 2000;292:795-802.
18. Simons M, Annex BH, Laham RJ, et al. Pharmacologic treatment of coronary artery disease with recombinant fibroblast growth factor-2 double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-793.